Inotiv Executive and Leadership Team

Robert Leasure, the Chief Executive Officer & President at Inotiv, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the integration of scientific capabilities across the drug discovery continuum, the Chief Executive Officer & President ensures that every client program receives attentive and decisive service. This leadership role involves managing the expansion of research model supply chains and maintaining the impeccable regulatory history that defines the company. By aligning the world-class team of scientists with evolving market demands, Robert Leasure drives the operational excellence required for on-time quality data delivery. The Chief Executive Officer & President maintains constant communication with the Board to ensure fiscal health and strategic growth. Through this focused approach, Leasure secures the company's position as a premier contract research organization for complex pharmaceutical projects.

Beth Taylor, the Executive Vice President & Chief Financial Officer at Inotiv, manages the financial health and capital allocation strategies of the organization. Overseeing the fiscal planning required to support the company's expansion in the research services market, the Executive Vice President & Chief Financial Officer ensures that resources align with long-term growth objectives. This leadership role involves managing investor relations, financial reporting, and the budgetary requirements of diverse scientific departments. By maintaining rigorous financial controls, Beth Taylor supports the company's ability to invest in world-class scientific talent and infrastructure. The Executive Vice President & Chief Financial Officer works closely with the executive team to evaluate potential acquisitions and strategic partnerships that enhance the company's service portfolio. Through disciplined financial management, Taylor provides the stability necessary for the organization to continue delivering high-quality research data to clients worldwide.

Greg Beattie, the Chief Operating Officer at Inotiv, manages the daily execution of scientific services and laboratory operations. Overseeing the complex logistics of critical research model supply, the Chief Operating Officer ensures that internal processes remain efficient and scalable. This leadership role involves coordinating cross-functional teams to maintain high standards of data integrity throughout the investigational new drug process. By optimizing laboratory workflows and resource allocation, Greg Beattie supports the company's commitment to delivering a superlative experience for every client. The Chief Operating Officer monitors performance metrics across all research facilities to guarantee that project timelines meet rigorous industry standards. Through meticulous oversight of operational infrastructure, Beattie enables the organization to handle diverse research projects with precision and reliability, ultimately strengthening the company's reputation for quality and scientific rigor.

Lizanne Muller, the Group President, RMS at Inotiv, oversees the specialized division responsible for the supply of critical research models, including rodents, rabbits, and nonhuman primates. Managing the operational standards for these essential biological assets, the Group President, RMS ensures that all models meet the highest quality and ethical benchmarks required for pharmaceutical research. This leadership role involves coordinating with global supply chains to guarantee the availability of models for diverse client projects. By maintaining rigorous oversight of the research model services division, Lizanne Muller supports the company's commitment to providing a foundation for successful drug development. The Group President, RMS works to integrate these services with the broader scientific capabilities of the organization, ensuring a seamless experience for clients. Through strategic management of these critical assets, Muller enables the company to maintain its position as a trusted partner in the scientific community.

Alison Bendele, the Founder and President of Bolder BioPATH at Inotiv, directs the specialized pathology and pharmacology research services that enhance the company's discovery capabilities. Overseeing the technical execution of complex bio-pathology studies, the Founder and President of Bolder BioPATH ensures that client programs receive expert scientific analysis. This leadership role involves managing the integration of specialized research methodologies into the broader Inotiv service continuum. By leveraging deep expertise in pathology, Alison Bendele drives the delivery of high-quality, actionable data that supports the investigational new drug process. The Founder and President of Bolder BioPATH collaborates with the wider scientific team to ensure that all research outcomes meet the company's standards for excellence. Through the focused application of specialized knowledge, Bendele strengthens the organization's ability to provide comprehensive support for pharmaceutical clients, ensuring that every project benefits from precise and reliable scientific insights.

Becky Dolliver, the Chief Information Officer at Inotiv, architects the digital infrastructure necessary to support advanced scientific research and data management. Overseeing the security and accessibility of sensitive client information, the Chief Information Officer ensures that all technological systems comply with stringent regulatory requirements. This leadership role involves implementing robust data platforms that facilitate the seamless transfer of research findings from discovery to clinical stages. By modernizing the digital tools used by the world-class team of scientists, Becky Dolliver drives efficiency and accuracy in data reporting. The Chief Information Officer collaborates with other executive leaders to integrate new software solutions that enhance the company's research capabilities. Through the strategic deployment of information technology, Dolliver protects the integrity of the research process and supports the company's mission to provide high-quality, reliable data to global pharmaceutical partners.

Jeff Krupp, the Chief Human Resources Officer at Inotiv, directs the talent acquisition and organizational development strategies that sustain the company's scientific workforce. Overseeing the recruitment of specialized researchers and laboratory staff, the Chief Human Resources Officer ensures that the organization maintains a world-class team capable of delivering superlative service. This leadership role involves fostering a culture of attentive and decisive performance across all departments. By implementing comprehensive training and development programs, Jeff Krupp supports the professional growth of employees who contribute to the company's regulatory success. The Chief Human Resources Officer collaborates with leadership to align human capital strategies with the company's broader mission of advancing drug discovery. Through the effective management of personnel policies and workplace culture, Krupp ensures that the organization remains a top destination for scientific talent, ultimately driving the quality and reliability of the research services provided.